KALA BIO, Inc. announces it has entered into securities purchase agreement with certain institutional investors to issue 10,901Series G Convertible Non-Redeemable Preferred Shares at a issue price of $788.90 per preferred share for gross proceeds of $8,599,798.9 on March 25, 2024. The transaction is expected to close on March 26, 2024. The transaction will include participation from 667, L.P. for 1,075 Preferred Shares and Baker brothers life sciences, L.P for 9,826 Preferred Shares.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | +1.94% | -4.40% | -10.00% |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
Mar. 29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.00% | 17.74M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP